SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two DLs of venetoclax were evaluated with an expansion cohort at the recommende...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathis, Anastasios, Mey, Ulrich, Schär, Sämi, Hitz, Felicitas, Pott, Christiane, Mach, Nicolas, Krasniqi, Fatime, Novak, Urban, Schmidt, Christian, Hohloch, Karin, Kienle, Dirk Lars, Hess, Dagmar, Moccia, Alden A., Unterhalt, Michael, Eckhardt, Katrin, Hayoz, Stefanie, Forestieri, Gabriela, Rossi, Davide, Dirnhofer, Stefan, Ceriani, Luca, Sartori, Giulio, Bertoni, Francesco, Buske, Christian, Zucca, Emanuele, Hiddemann, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278307/
https://www.ncbi.nlm.nih.gov/pubmed/35537101
http://dx.doi.org/10.1182/bloodadvances.2021006520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278307/
https://www.ncbi.nlm.nih.gov/pubmed/35537101
http://dx.doi.org/10.1182/bloodadvances.2021006520

Ejemplares similares